Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Eklund Foundation for Odontological Research and Education opens for applications of up to €250,000

Researchers within dentistry will soon be able to apply for grants of up to €250,000, which is the total sum allocated by the Eklund Foundation in 2024. The application portal will be open 1-31 May, welcoming applicants from all parts of the world in all fields of dentistry.Both experimental and clinical studies within all fields of dentistry are accepted, but the foundation will prioritise projects that can be related to periodontology, implantology, or cariology. Researchers may apply for funding for a project in its entirety or for part of a project.   Even though the application

poLight ASA: Approval and Publication of Supplemental Prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Reference is made to the stock exchange announcement by poLight ASA (the "Company" or "poLight") on 24 April 2024 regarding the publication of its audited consolidated financial statements as at, and for the year ended, 31 December 2023 (the "2023 Financial Statements"), and to the stock

BioStock: BioInvent selected to present at ASCO in Chicago

BioInvent has been selected to present two posters at the American Society for Clinical Oncology Annual Congress (ASCO 2024) in Chicago from May 31 to June 4. The presentations will focus on data from the company’s clinical studies with the lead drug candidates BI-1808 and BI-1206, both in phase I/IIa development in combination with MSD’s Keytruda. BI-1808 is also evaluated as single agent, which will also be included in the presentation.Read the article at biostock.se: https://www.biostock.se/en/2024/04/bioinvent-selected-to-present-at-asco-in-chicago/ This is a press release from

No updates on the Optomed Aurora AEYE FDA clearance process

Optomed Plc Stock Exchange Release 29 April 2024 at 13:20, Helsinki No updates on the Optomed Aurora AEYE FDA clearance process Optomed is together with its partner AEYE Health in the process of obtaining a clearance for the AI fundus camera Optomed Aurora AEYE.   At this stage, Optomed does not have any new information regarding the FDA clearance process. Optomed will update market as new information becomes available.   Optomed Plc Further enquiries Juho Himberg, CEO, juho.himberg@optomed.com       Optomed in Brief  Optomed is a Finnish medical

Teesside University students creating AI controlled self-driving car

Students from Teesside University are helping to develop an artificial intelligence (AI) controlled self-driving car, with testing sessions already taking place on campus.Led by Dr Alexander Ellin in the University’s School of Computing, Engineering & Digital Technologies, the team of students and staff are creating the AI controlled car as a test vehicle to help students compete in the renowned IMECHE engineering competition Formula Student. The Formula Student competition, held each year at legendary motor racing circuit Silverstone, is Europe's best known educational engineering

Section 430(2b) statement

29 April 2024   Moonpig Group plc Section 430(2B) Companies Act 2006 Statement Moonpig Group plc (the “Company”) announced on 26 April 2024 that Simon Davidson had resigned as a director of the Company with effect from 25 April 2024.  Under the Relationship Agreement between the Company and Exponent Private Equity LLP (“Exponent”) Simon’s fees as Exponent’s Nominee Director are paid directly to Exponent and will be paid up to and including the date of termination of 25 April 2024. No other remuneration payment will be made by the Company to Simon or to Exponent after Simon

Vattenfall's Annual General Meeting 2024

Vattenfall's Annual General Meeting 2024Vattenfall’s owner was represented at the AGM voting by Gustaf Hygrell at the Ministry of Finance. Annual General Meeting decisions: Adoption of balance sheet and income statement The AGM adopted the income and balance sheet for Vattenfall AB and the Vattenfall Group. Dividend The AGM decided on a dividend distribution of SEK 4 000 000 000 to the owner of the parent company for 2023. Discharge of liability The AGM decided to discharge the members of the board and the CEO from liability. Renumeration report and guidelines for

Thomas Magnussen appointed as Country Manager, Norway

Thomas Magnussen appointed as Country Manager, Norway as of May 1, 2024. He succeeds Trond Wiker, who has been appointed in another role in iLOQ. Before joining iLOQ, Thomas worked in a National and International sales role for Caverion Norge AS. He has a strong background in the security and locking industry in Norway and the Nordics. “I am honored to be a part of the iLOQ family and very excited to take on the role of Country Manager. After many years on the integrator side, I really look forward to bringing all this experience into the growth potential for iLOQ. And,

Nokian Tyres plc Interim Report January–March 2024: Building the new Nokian Tyres on track in a challenging environment

Nokian Tyres plc Interim Report January–March 2024, April 29, 2024 at 1:00 p.m. EEST   This release is a summary of Nokian Tyres’ Interim Report January–March 2024. The complete report is attached to this release. It is also available on the company’s website at www.nokiantyres.com/company/investors/.   January–March 2024  · Net sales were EUR 236.6 million (January–March 2023: 236.4). With comparable currencies, net sales increased by 1.4%. · Segments operating profit was EUR -15.1 million (-14.1). Operating profit was EUR -26.2 million (-18.8). EUR -11.1 million (-4.7)

Aker Carbon Capture ASA: Minutes of Annual General Meeting

The 2024 Annual General Meeting of Aker Carbon Capture ASA was held today as a digital meeting with online participation.All resolutions were made in accordance with the proposals set out in the meeting notice. Minutes of the meeting are attached and available on https://akercarboncapture.com/investors/general-meetings/. The articles of association were amended in accordance with the proposal. The number of board members was reduced to three, and the general meeting re-elected Kristian Monsen Røkke as the Chair of the Board of Directors, and Karl Erik Kjelstad as new deputy. ENDS

United Bankers Plc’s directed share issues to employees and tied agents and the related matching share plans

  United Bankers Plc STOCK EXCHANGE RELEASE 29 April 2024 at 12:45 EEST   United Bankers Plc’s directed share issues to employees and tied agents and the related matching share plans The Board of Directors of United Bankers Plc has today resolved to organise an employee share issue, offering new shares in the Company for subscription by the employees and management (including Managing Directors) of the United Bankers Group (the ”Employee Share Issue”). Furthermore, the Board of Directors resolved to organise a directed share issue to the tied agents of the United

Tobii publishes 2023 Annual and Sustainability Report

Tobii’s Annual Report and Sustainability Report for 2023 is as of today available on the company’s website.The Annual and Sustainability Report in Swedish as well as an English translation are available in PDF format at: https://corporate.tobii.com/investors. The Swedish version is also available in European Single Electronic Format (ESEF). For more information, please contact: Carolina Strömlid, Head of Investor Relations, Tobii AB, +46 (0)70 880 71 73, email: carolina.stromlid@tobii.com   This information is information that Tobii AB is obliged to make public pursuant to

Invitation to the presentation of the Q1 2024 results on Tuesday 7 May 2024 at 10:00 (CET)

Nordic Mining hereby invites you to the presentation of the results for the first quarter of 2024 and company update on Tuesday 7 May 2024 at 10:00 (CET). The presentation will be held digitally. The interim report and the presentation will be published at the Oslo Stock Exchange and on Nordic Mining's webpage (www.nordicmining.com) in advance of the presentation. The presentation and Q&A session will be held in English and transferred via webcast. You will have the opportunity to post questions online throughout the webcast session. The webcast will be available on: https://channel.

Medivir brings the Q1 webcast forward to 10 a.m. on April 30

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET. The webcast is brought forward as Nasdaq Stockholm closes earlier.       For additional information, please contactMagnus Christensen, CFO, Medivir ABTelephone: +46 8 5468 3100E-mail: magnus.christensen@medivir.com         About Medivir Medivir develops innovative drugs with a focus

SAS TO JOIN SKY TEAM ALLIANCE

· SkyTeam and SAS, flag carrier of Scandinavia, have signed an Alliance Adherence Agreement concluding that SAS will join SkyTeam on 1 September 2024. · SAS customers will benefit from seamless products as well as enjoy more travel options to several previously unserved destinations. · All EuroBonus members will benefit from earning and burning points, while Gold and Diamond members will enjoy SkyPriority services and lounge access.AMSTERDAM/STOCKHOLM, 29 APRIL 2024 - Today marks an exciting milestone as SkyTeam and SAS have officially signed an Alliance Adherence Agreement (AAA),

Immunovia publishes the annual report for 2023

LUND, SWEDEN – Immunovia AB (publ) today announced that the Annual Report for 2023 has been published.  The annual report can be downloaded in pdf format and is available on Immunovia’s website: https://investor.immunovia.com/financial-reports-presentations/.     For more information, please contact: Karin Almqvist Liwendahl Chief Financial Officer karin.almqvist.liwendahl@immunovia.com +46 709 11 56 08   Immunovia in brief  Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2023/24

EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2023/24, on Tuesday, May 14[th], after stock markets closing.At 10.00 (CET) 15[th] May, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the year-end report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/ysf2a9te Date and time May 15[th], 2024, at 10.

BioStock: MDR certification was Enzymatica’s highlight in Q1

Enzymatica has recently published its Q1 report, where the MDR certification for ColdZyme stands out as the key milestone during the quarter.– The MDR certification was a labor-intensive and costly process, but now that ColdZyme has been certified as one of the first cold products in Europe, it opens up great commercial opportunities.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/mdr-certification-was-enzymaticas-highlight-in-q1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Bianca Nobilo appointed Head of External Affairs at IFS

Breaking News: CNN Anchor joins IFS executive team to support AI-driven growthLondon, UK, April 29th, 2024 – IFS, the fastest growing cloud enterprise software company in the world, has today appointed former CNN News Anchor & Correspondent Bianca Nobilo as the company’s Head of External Affairs. Nobilo joins the executive leadership team at IFS to direct Government Relations, Industry Relations and External Affairs & Communications. IFS’s remarkable growth across 80 countries is fueled by the company’s powerful artificial intelligence technology, industry depth and customer centric

Cabonline Group Holding Annual Report and Sustainability Report 2023

Cabonline Group Holding´s Annual Report 2023 and Sustainability Report 2023 are now available at cabonlinegroup.com/en/about/investor/financial-reports . See also enclosed PDFs. The Swedish annual report is also available on the Group's website in the European Single Electronic Format (ESEF).For more information, please contactCharlotta Söderlund, CEO, phone +46 70 453 77 70, charlotta.weigel@cabonline.comErik Skånsberg, CFO, phone +46 79 062 38 84, erik.skansberg@cabonline.com About Cabonline GroupCabonline is the

Optomed’s January-March 2024 interim report will be published on 7 May 2024

Optomed Plc Press Release 29 April 2024 at 11.00, Helsinki Optomed’s January-March 2024 interim report  will be published on 7 May 2024 Optomed will publish its January-March 2024 interim report on 7 May 2024 approximately at 9.00 EET.   A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EET/10.00 CET. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.   The participants are requested to register for the call in advance by email to sakari.

Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in hepatocellular carcinoma (HCC) has been accepted for presentation at the European Society for Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress in June 26-29, 2024 in Munich.   The abstract, titled “Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-

Brain+ announces a change in its Financial Calendar for 2024

Copenhagen, Denmark, April 29, 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  ·Brain+ will publish its Annual Report for 2023 on May 7, 2024   ·On April 30, 2024, the company will issue an announcement of its un-audited Annual Financial Statements for 2023Brain+ A/S (‘Brain+’ or ‘the Company’) will publish its Annual Report for 2023 on May 7, instead of on April 30, 2024, as previously stated in the Financial Calendar on the Company’s website.   The reason for the change in the publication date for Brain+’ Annual Report for 2023 is that the Company has an outstanding

There are no items matching the current filter
There are no more items matching the current filter
Back to top